Pafolacianine sodium injection could be a real-time adjunct to current surgical practice for ovarian cancer, allowing for more lesions to be removed at the time of surgery, according to a study presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.
According to a press release2 from the manufacturer of pafolacianine sodium, many ovarian cancers overexpress folate receptors to enable uptake of folic acid. Pafolacianine sodium is a novel molecule that binds to folate receptors and illuminates intraoperatively under near-infrared light.
The following article features coverage from the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. Click here to read more of Cancer Therapy Advisor‘s conference coverage.